Cometriq 20mg tablets |Cabozantinib | MHP

COMETRIQ 20MG

DESCRIPTION:

Cometriq 20mg is a prescription medicine required to treat people with medullary thyroid cancer (MTC) which has spread to other parts of the body known as metastatic MTC.
Cometriq 20mg is highly protein bound and there is a hypothetical risk that it will displace combination with warfarin, so INR monitoring is recommended.
Cometriq 20mg is not known if using in children safe and effective.

INDICATION:

Cometriq 20mg is Indicated for following conditions;
The treatment of Metastatic medullary thyroid cancer
The treatment of Advanced renal cell carcinoma (RCC) who have getting before anti-angiogenic therapy.
The treatment of Hepatocellular cancer who have previously received sorafenib.

MECHANISM OF ACTION:

Cabozantinib is also known as targeted therapy which aims and attach to the tyrosine kinase receptors and prohibits the activity of multiple tyrosine kinases, contains RET, MET, and VEGF on the surface of the cell.
By connecting to these receptors, Cabozantinib stops important pathways which develop cell division.

COMETRIQ 20MG TABLETS

PRODUCTS DEATIALS:

Brand :Cometriq
Ingredients : Cabozantinib
Strength : 20mg
Manufactured : Exelixis.Inc
Package : 30 tablets

ADME:

Maximum plasma concentration is observed in 2-5 hours
Human serum protein bounding of Cometriq is ≥ 99.7%
Mostly metabolized by CYP3A4 and minorly by CYP2C9.
The drug excreted mostly via feces 54 % and in urine 27% and half-life is 55 hours.

DOSAGE MANAGMENT :

Do not substitute Cometriq tablets with Cabozantinib capsules.
The prescribed dose of Cometriq is 60 mg.
Administration Cometriq is without food.
Tell the patients don’t not havefood for at least 2 hours before and 1 hour after taking Cometriq.
Continue the treatment until patient no longer experiences clinical benefit or experiences unacceptable toxicity.
Swallow Cometriq tablets whole. Do not crush Cometriq tablets.

PRECUATIONS:

• Interrupt the Cometriq 20mg in patients who develop an acute myocardial infarction, cerebral infarction, or any other clinically significant arterial thromboembolic complication.
• Interrupt the Cometriq 20mg for patient if have severe hypertension that cannot be controlled with anti-hypertensive therapy.
• Check the patients for symptoms of perforations and fistulas, included abscess. discontinue Cometriq 20mg in patients who experience a perforation or a fistula.
• Avoid administration Cometriq 20mg to patients with a present history of patients with haemorrhage or haemoptysis.
• Advice pregnant women about possible risk to a foetus. Hence inform females of reproductive possible to use effective contraception during treatment with Cometriq 20mg and for 4 months after the last dose.

SIDE EFFECTS:

• GI perforations and fistulas
• Thrombotic events
• Hypertension and hypertensive crisis
• Diarrhea
• Palmar-plantar erythrodysesthesia
• Haemorrhage
• Reversible posterior leukoencephalopathy syndrome
• Weight loss
• Decreased appetite
• Nausea
• Fatigue
• Oral pain
• Neutropenia
• Low platelets
• Taste changes
• Hair colour changes
• High blood pressure
• Low potassium
• Hair loss
• Dizziness
• Joint pain
• Swallowing trouble
• Muscle spasms
• Dyspepsia (indigestion)
• Skin redness
• Reduced sodium

DRUG INTERACTION:

Concurrent use of Cometriq with strong CYP3A4 inhibitor will have high the single dose plasma Cometriq 20mg exposure by 38%.
Co administration of Cometriq with strong CYP3A4 inducers will decreased the single dose plasma Cometriq 20mg exposure by 77%
Interaction of Cometriq with MRP2 inhibitors may increase the exposure to Cometriq 20mg.

CONTAINDICATION:

The drug Cometriq 20mg is contraindicated to Hypersensitivity reaction in patients

PREGNANCY:

Pregnancy Category is D: Based on studies of animal and mechanism of action, Cometriq 20mg will cause risk to fetus when given to pregnant women.
Avoid pregnancy while on treatment with cometriq 20mg.

LACTATION:

Advise the women not to breastfed to infants while on treatment with Cometriq 20mg drugs because of possible risk to the fetus.

STORAGE:

Store the drug at 20°C to 25°C
Keep away from the children resistances

CONTACT US:

PHONE NO:+91-9940472902

EMAIL:millionhealthpharmaceuticals@gmail.com

WEBSIDE URL:https://millionpharma.com/cometriq-20mg.php